Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16116793 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 | |
| SCHEMBL15214349 | 0.85 | MAPT (0.49) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 | |
| SCHEMBL20356626 | 0.85 | CXCR4 (0.45) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 | |
| SCHEMBL12028958 | 0.84 | DRD2 (0.43) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 | |
| SCHEMBL15999335 | 0.84 | DRD2 (0.43) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 | |
| SCHEMBL17967834 | 0.83 | KMT2A (0.50) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 | |
| SCHEMBL12766995 | 0.82 | MAPT (0.47) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL7838680 | 0.82 | KMT2A (0.49) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 | |
| SCHEMBL465740 | 0.82 | BACE1 (0.43) | CHRM2CHRM1CHRM3 | |
| SCHEMBL15906686 | 0.82 | CXCR4 (0.41) | SMN1; SMN2MAPTPDE2AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326986-B2 | Quinazolinone, quinolone and related analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306612-A1 | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | SMN1; SMN2 3331/4885MAPT 1270/4885PDE2A 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.